MedTrace Logo

Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors

NCT01642342 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 102

Last updated 2022-08-24

No results posted yet for this study

Summary

This study is about an experimental drug called sEphB4-HSA (recombinant albumin fusion protein sEphB4-HSA). This research study will be the first time sEphB4-HSA is given to people. sEphB4-HSA prevents tumor cells from multiplying and blocks several compounds that promote the growth of blood vessels that bring nutrients to the tumor. sEphB4-HSA has shrunk colon, lung, breast, glioma, melanoma, prostate and Kaposi's sarcoma tumors in mice

Conditions

  • Unspecified Adult Solid Tumor, Protocol Specific

Interventions

OTHER

laboratory biomarker analysis

Correlative studies

OTHER

pharmacological study

Correlative studies

BIOLOGICAL

recombinant albumin fusion protein sEphB4-HSA

Given IV

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Vasgene Therapeutics, Inc

    collaborator INDUSTRY

  • The V Foundation for Cancer Research

    collaborator OTHER

  • University of Southern California

    lead OTHER

Principal Investigators

  • Anthony El-Khoueiry · University of Southern California

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-09-06
Primary Completion
2019-05-29
Completion
2019-05-29
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01642342 on ClinicalTrials.gov